Floatz logo

A-DMDT390-BISFV(UCHT1)

Stage IV Melanoma

Virogen Biotechnology Inc.protein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Stage IV Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Therapeutic Autologous Lymphocytes
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

A-DMDT390-BISFV(UCHT1) is also rated in:

mycosis fungoidesDormant
CCC
Indicative ·
54 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
T-cell leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →